Clinical characteristics, patterns of lipid-lowering medication use, and health care resource utilization and costs among patients with atherosclerotic cardiovascular disease

Thomas P Power1
Xuehua Ke2
Zhenxiang Zhao3
Nicole Gidaya Bonine2
Mark J Cziraky2
Michael Grabner2
John J Barron2
Ralph Quimbo2
Burkhard Vangerow2
Peter P Toth4,5

1AIM Specialty Health, Chicago, IL,
2HealthCare, Inc., Wilmington, DE,
3Eli Lilly and Company, Indianapolis, IN,
4CGH Medical Center, Sterling, IL,
5Johns Hopkins University School of Medicine, Baltimore, MD, USA

Purpose: The aim of this study was to investigate real-world patient characteristics, medication use, and health care resource utilization (HCRU) and costs among patients with clinical atherosclerotic cardiovascular disease (ASCVD) as defined by 2013 American College of Cardiology/American Heart Association (ACC/AHA) guidelines, to examine burden of disease and unmet needs, such as potential undertreatment.

Patients and methods: This retrospective cohort study utilized a nationally representative managed care database to identify newly diagnosed ASCVD patients between January 1, 2007, and November 30, 2012 (index = first ASCVD diagnosis date) in the USA. Patients had ≥12-month pre-index (baseline) and ≥12-month post-index (follow-up) health plan enrollment and had no baseline lipid-lowering medication (LLM). Patient characteristics, LLM utilization patterns, HCRU, and costs were examined for all patients and by subgroups based on LLM use pattern and/or follow-up low-density lipoprotein cholesterol (LDL-C) levels.

Results: A total of 128,017 ASCVD patients were identified with a mean (SD) age of 59 (13) years, 43.1% female, and 48.8% with ≥36-month follow-up. Within 12-month follow-up, 10.6% had high-intensity statins and 56.9% had no LLM fills. Baseline mean (SD) all-cause costs were $8,852 ($25,608). At 12-month follow-up, mean (SD) all-cause and ASCVD-related costs were $31,443 ($54,040) and $20,289 ($45,159), respectively. The 36-month analyses showed similar distributions. Multivariable analyses showed that age, gender, region, health insurance type, baseline comorbidities, baseline use of specific medications, baseline lipid profiles, and index ASCVD type were significantly associated with all-cause and ASCVD-related health care costs.

Conclusion: Patients have nonoptimal treatment for ASCVD and substantial HCRU and costs associated with residual risk. Unmet needs and cost burdens of ASCVD patients merit additional investigation.

Keywords: ASCVD, low-density lipoprotein cholesterol, lipid-lowering medications, health care resource utilization and costs, statins, treatment patterns, guidelines, real-world evidence

Introduction

Clinical atherosclerotic cardiovascular disease (ASCVD), constituted of acute coronary syndrome (ACS), history of myocardial infarction, stable or unstable angina, coronary or other arterial revascularization, stroke, transient ischemic attack, or peripheral arterial disease presumed to be of atherosclerotic origin, is the leading cause of death for both men and women in the USA.1 Approximately 370,000 deaths annually in the USA are attributable to coronary heart disease (CHD).1 Heart-related conditions could intensify
as the US population ages – the ≥65-year-old population is projected to approximately double by 2030. The American Heart Association (AHA) forecasts that 40.5% of the US population will have some form of cardiovascular disease by 2030 – and between 2010 and 2030, the total direct medical costs of cardiovascular disease will increase threefold from $273 billion to $818 billion.

Hypercholesterolemia has been identified as one of the major risk factors for ASCVD, and numerous trials have demonstrated the clinical benefits of low-density lipoprotein cholesterol (LDL-C) reduction in both primary and secondary prevention settings.

The 2013 American College of Cardiology (ACC)/AHA guidelines for the treatment of hypercholesterolemia represent an important shift from the previous approach, which entailed treatment to achieve risk-stratified LDL-C goals defined by estimated 10-year risk for an acute cardiovascular event. Specifically, the 2013 guidelines identified four major statin benefit groups: 1) individuals with clinical ASCVD, 2) individuals with primary elevations of LDL-C ≥190 mg/dL, 3) individuals with diabetes aged 40–75 years with LDL-C 70–189 mg/dL and without clinical ASCVD, or 4) individuals without clinical ASCVD or diabetes with LDL-C 70–189 mg/dL and estimated 10-year ASCVD risk ≥7.5%.

Among patients with clinical ASCVD, high-intensity statin therapy is recommended for those aged ≤75 years, unless contraindicated. Moderate-intensity statin therapy is recommended for patients aged ≥75 years or those who are not candidates for high-intensity statins. In addition, no guideline recommendations are made for or against specific LDL-C or non-high-density lipoprotein cholesterol (non-HDL-C) goals for the primary and secondary prevention of ASCVD.

It has been estimated that use of the 2013 guidelines as an alternative to the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP-III) recommendations would increase statin eligibility by 11% in the USA, or by 12.8 million patients. A small retrospective study based on electronic health records to assess the impact of the new guidelines concluded that broad adoption of the 2013 guidelines would likely expand statin prescription rates among patients in the fourth statin benefit group as defined by the 2013 guidelines. Another estimate by suggested that, among potential candidates for cholesterol-lowering treatments, compared to the benchmarks in 2013, there would be a 25% increase in the proportion of patients treated with statins over 2014–2016, during which prescriptions for non-statin cholesterol-lowering agents will decrease by 68%. Additional evaluation of ASCVD patient clinical characteristics, treatment patterns, and health care resource utilization (HCRU) and costs in the short term and long term prior to implementation of the 2013 guidelines using both the old and new guideline measures may help to better understand the potential impact of the 2013 guidelines on patients with clinical ASCVD.

This study investigated real-world patient demographic and clinical characteristics, patterns of lipid-lowering medication (LLM) utilization, and HCRU and costs, specifically through the lens of the old and new guideline measures, among patients with clinical ASCVD as defined by the 2013 ACC/AHA guidelines to better understand the burden of disease and unmet needs in this population.

**Patients and methods**

**Study design and patient identification**

This observational, retrospective cohort study utilized medical and pharmacy claims along with laboratory results of enrollees in 14 regionally dispersed health plans in the USA from the broadly, nationally representative HealthCore Integrated Research Database (HIRD®), for the study period of January 1, 2006, through November 30, 2013. The targeted study population of interest consisted of patients with incident clinical ASCVD. To identify this target study population within the HIRD, patients with an ASCVD diagnosis (including ACS, CHD, atherosclerotic cerebrovascular disease [ACD], and peripheral artery disease [PAD]) were selected during the intake period (January 1, 2007, to November 30, 2012). ASCVD diagnosis was defined as either ≥1 inpatient or emergency room (ER) visit with any ASCVD ICD-9-CM diagnosis codes in the primary diagnosis position, or ≥2 physician office or other outpatient visits that were 30 days apart with ASCVD ICD-9-CM diagnosis codes within the same ASCVD group (Table S1). The earliest medical claim that qualified as an ASCVD diagnosis for an inpatient, ER, or outpatient encounter within the intake period was defined as the index date, which represents the date of incident clinical ASCVD for each patient. All study data were managed in strict compliance with the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule, and data de-identification procedures were employed to preserve patient anonymity and confidentiality throughout the study process. Institutional review board (IRB) approval was not required for this administrative claims-based study as HealthCore, Inc. is a business associate of the covered entities for which the administrative claims data was used and maintains data use agreements to conduct research using that data in the form of a limited data set.
Inclusion/exclusion criteria
For inclusion, patients were required to be ≥18 years on the index date, be enrolled only in commercial or Medicare Advantage Plans during the study period, and have ≥12-month pre- and ≥12-month post-index continuous health plan enrollment. To focus on patients with new-onset clinical ASCVD in relation to the index date, patients with ≥1 ASCVD claim(s) in the 12-month pre-index period were excluded. In order to focus on initiation and subsequent utilization of LLM, we excluded patients with any LMM claim during the 12-month pre-index period.

Study measures
Demographic and clinical characteristics
Patients’ demographic characteristics (on index date) included age, gender, health plan type (health maintenance organization [HMO], preferred provider organization [PPO], or others), Medicare Advantage coverage, and geographic region of their health plan. Clinical characteristics included the type of ASCVD on index date and baseline (12-month pre-index period) clinical characteristics such as Quan-Charlson Comorbidity Index (QCI), selected comorbidities of interest (including chronic kidney disease, diabetes, dyslipidemia, hypertension, obesity, anxiety, depression, and pain), use of non-LLM, and lipid panel values (for a subset of patients with directly available laboratory results). Lipid panel values including LDL-C, high-density lipoprotein cholesterol (HDL-C), triglycerides, total cholesterol, and non-HDL-C were measured at baseline and at 12- and 36-month follow-up. Baseline lipid panel values were measured in the year prior to the index date including up to 15 days after the index date; follow-up lipid panel values were measured at the end of the 12-month follow-up (index date + 364 days ± 90 days) and at the end of the 36-month follow-up (index date + 1,094 days ± 90 days). In cases with ≥1 baseline value for the same lipid measure, the result closest to index date was used. When multiple follow-up lipid values were available, the results closest to the end date of each discrete follow-up period (12- and 36-month periods) were used for evaluation.

LLM utilization patterns
The index LLM was defined as the first LLM prescription (either monotherapy or combination therapy) filled by a patient within 6 months following the diagnosis of ASCVD. The earliest fill date of the index LLM was defined as the index fill date. The index LLM dose titration (up, down, and no change), discontinuation/persistence, switching, and augmentation were examined within both the 12- and 36-month follow-up periods among a subset of patients who initiated a monotherapy LLM on the index fill date and had at least 12 and 36 months of observational follow-up time from index date.

Discontinuation of the index LLM was defined as no refill for the index LLM within 45 days following the depletion of the preceding fill’s days of supply per the pharmacy claim. The evaluation of discontinuation of the index LLM (i.e., time until discontinuation and persistence) was limited to the first observed discontinuation and did not account for subsequent restarts of the index LLM. A switch from the index LLM was defined as a fill of a non-index LLM within 45 days from the first discontinuation date and no more fills of the index LLM within 6 months after the discontinuation date. Evaluation of switches from the index LLM (i.e., time to a switch from the index LLM) was limited to the first observed switch only. Persistence was defined as the time from initiation until discontinuation of the index LLM; in cases without discontinuation, persistence was measured as the time from initiation of the index LLM to the end of follow-up. Augmentation was defined as the addition of a non-index LLM while a patient was persistent with the index LLM. Overall, LLM use patterns were examined at 12-month follow-up among all patients and at 36-month follow-up among those with ≥36-month post-index health plan enrollment.

HCRU and costs
All-cause and ASCVD-related HCRU and costs were derived from medical claims for inpatient hospitalizations, ER visits, physician office visits, and other outpatient visits/services and from pharmacy claims for prescription medications. HCRU and costs occurring on the index date were included in the follow-up period. Costs incorporated both health plan and patient payments. Patient out-of-pocket costs included coinsurance, deductibles, co-payments, and any other patient outlays for specific claims. ASCVD-related medical costs were derived from medical claims with any ICD-9-CM diagnosis code(s) for ASCVD during the 12- and 36-month follow-up periods. ASCVD-related pharmacy costs were computed from pharmacy claims for ASCVD-related medications including LLMs, anti-claudication medications, antidiabetic medications, antihypertensive medications, digoxin, prescription antiplatelet and anticoagulant medications, and prescription omega 3 fatty acids during the 12- and 36-month follow-up periods. All costs were adjusted to 2013 US$ values based on the consumer price index for medical care from the US Bureau of Labor Statistics.19
Patient subgroups
Patients were categorized into different non-mutually exclusive subgroups based on their index LLM therapy or LDL-C status observed during the study follow-up: 1) whether or not patients were on high-intensity statins (defined as statins lowering LDL-C by approximately ≥50%; including atorvastatin 40 or 80 mg and rosvastatin 20 or 40 mg) in all four calendar quarters after the index date (or, for patients with 36 months of follow-up, at least two calendar quarters in each year of follow-up), 2) whether or not patients had >50% follow-up LDL-C reduction, 3) whether or not patients had follow-up LDL-C <70 mg/dL, and 4) whether or not patients had follow-up LDL-C <100 mg/dL at 12- and 36-month follow-up.

Statistical analysis
Descriptive statistics, including mean (SD and median) and absolute/relative frequencies for continuous and categorical data, respectively, were reported. Due to the non-normal distribution and skewed nature of the cost data, generalized linear models (GLMs) with gamma distribution and log link were used to examine the association of patient factors such as baseline patient demographic and clinical characteristics with total all-cause and ASCVD-related health care costs (dependent variables) within 12 months of follow-up.

Results
Demographic and clinical characteristics
Study patients (N = 128,017) had a mean (SD, median) age of 59 (13, 58) years, 43.1% were female, and 48.8% had ≥36-month follow-up. The largest proportion of patients had health plans located in the Midwest (39.0%), followed by 24.4% in the Northeast. Almost two-thirds (63.1%) of the patients were enrolled in PPO health plans, as summarized in Table 1. The index event was ACS in 64.1% of patients who received high-intensity statin therapy in all four quarters following the index date. The most common baseline comorbidities of interest included pain (63.7%), hypertension (47.0%), dyslipidemia (35.3%), and diabetes mellitus (16.4%). At baseline, ≥1 laboratory value was available for 20.8% (n = 26,653) of patients for LDL-C; 21.1% (n = 26,964) for HDL-C; 21.2% (n = 27,196) for triglycerides; and 21.3% (n = 27,292) for total cholesterol. Approximately one-quarter (21.0%, n = 26,924) of patients had ≥1 non-HDL-C value available. Among patients with baseline LDL-C values available, approximately 31.1% and 6.8% patients had LDL-C <100 mg/dL and <70 mg/dL, respectively. For patients with available baseline HDL-C values, 65.5% had desirable HDL-C levels (defined as >40 mg/dL for males and >50 mg/dL for females). Antihypertensive medications (45.3%) were the most commonly filled baseline medications, followed by antidiabetic medications (9.8%) and prescription antiplatelet and anticoagulant medications (6.9%).

Use of LLMs at 12- and 36-month follow-up
Index LLM
Within 6 months after the index date, 61.4% had no fills for any LLM; 7.8% of the patients had initiated high-intensity statin monotherapy; 27.8% had initiated moderate-/low-intensity statin monotherapy; 1.6% had initiated non-statin monotherapy; and 1.4% had initiated combination therapy (data not shown in tables or figures).

Index LLM use by monotherapy initiators at 12- and 36-month follow-up
As summarized in Table 2, among all monotherapy initiators with 12-month follow-up (n = 47,587), 54.5% discontinued index LLM, 9.6% switched their index LLM, 8.8% had up-titration of index LLM, and 2.9% augmented index LLM within the 12-month follow-up. For monotherapy initiators with 36-month follow-up (n = 21,198), 77.8% discontinued index LLM, 13.8% switched their index LLM, 12.4% had up-titration of index LLM, and 2.8% augmented index LLM over the 36-month follow-up period.

LLM use among all patients at 12- and 36-month follow-up
Overall, LLM utilization patterns among all patients showed that 41.4% received statins, 10.6% had high-intensity statins, 5.8% had been treated with ≥2 types of statins, 4.9% had both statins and non-statin LLMs, and 56.9% had no LLM within 12 months of follow-up. Among all patients, the mean (SD, median) number of LLM drug classes and LLM drug types filled within 12 months of follow-up was 0.5 (0.6, 0) and 0.5 (0.7, 0), respectively. Among patients with ≥36 months of follow-up, 49.7% had statins, 13.0% had high-intensity statins, 12.8% had been treated with ≥2 types of statins, 9.3% had both statins and non-statin LLMs, and 47.9% had no LLM during the 36-month follow-up period. Among patients with ≥36 months of follow-up, the mean (SD, median) number of LLM drug classes and LLM drug types filled during the 36-month follow-up period was 0.6 (0.7, 1) and 0.8 (0.9, 1), respectively (data not shown in tables or figures).
Table 1  Baseline demographic and clinical characteristics of ASCVD patients

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>All patients</th>
<th>Filled high-intensity statins in all first four quarters</th>
<th>With &gt;50% LDL-C reduction at 12-month follow-up</th>
<th>With LDL-C &lt;70 mg/dL at 12-month follow-up</th>
<th>With LDL-C &lt;100 mg/dL at 12-month follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients</td>
<td>128,017</td>
<td>6,044</td>
<td>865</td>
<td>3,556</td>
<td>9,636</td>
</tr>
<tr>
<td>Mean age (SD), median</td>
<td>59 (13)</td>
<td>55 (10)</td>
<td>60 (11)</td>
<td>60 (12)</td>
<td>60 (12)</td>
</tr>
<tr>
<td>Female</td>
<td>55,136</td>
<td>1,351</td>
<td>281</td>
<td>1,111</td>
<td>3,568</td>
</tr>
<tr>
<td>Geographic region</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Northeast</td>
<td>31,179</td>
<td>1,163</td>
<td>354</td>
<td>1,367</td>
<td>3,978</td>
</tr>
<tr>
<td>Midwest</td>
<td>49,979</td>
<td>2,503</td>
<td>189</td>
<td>865</td>
<td>2,215</td>
</tr>
<tr>
<td>South</td>
<td>23,450</td>
<td>1,285</td>
<td>199</td>
<td>734</td>
<td>1,967</td>
</tr>
<tr>
<td>West</td>
<td>23,409</td>
<td>1,093</td>
<td>93</td>
<td>590</td>
<td>1,476</td>
</tr>
<tr>
<td>Insurance plan type</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HMO</td>
<td>41,398</td>
<td>1,585</td>
<td>433</td>
<td>1,690</td>
<td>4,786</td>
</tr>
<tr>
<td>PPO</td>
<td>80,762</td>
<td>4,056</td>
<td>398</td>
<td>1,717</td>
<td>4,501</td>
</tr>
<tr>
<td>Others</td>
<td>5,857</td>
<td>403</td>
<td>34</td>
<td>149</td>
<td>349</td>
</tr>
<tr>
<td>Type of ASCVD</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACS</td>
<td>26,887</td>
<td>3,873</td>
<td>298</td>
<td>1,233</td>
<td>2,564</td>
</tr>
<tr>
<td>CHD</td>
<td>71,884</td>
<td>4,473</td>
<td>599</td>
<td>2,364</td>
<td>6,044</td>
</tr>
<tr>
<td>PAD</td>
<td>22,311</td>
<td>511</td>
<td>90</td>
<td>431</td>
<td>1,276</td>
</tr>
<tr>
<td>QCI, mean (SD), median</td>
<td>0.86 (1.41)</td>
<td>0.46 (1.05)</td>
<td>0.86 (1.41)</td>
<td>0.96 (1.44)</td>
<td>0.94 (1.41)</td>
</tr>
<tr>
<td>Selected comorbidities of interest</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anxiety</td>
<td>9,619</td>
<td>320</td>
<td>44</td>
<td>180</td>
<td>549</td>
</tr>
<tr>
<td>Chronic kidney disease</td>
<td>4,161</td>
<td>79</td>
<td>24</td>
<td>115</td>
<td>299</td>
</tr>
<tr>
<td>Depression</td>
<td>7,599</td>
<td>232</td>
<td>44</td>
<td>156</td>
<td>423</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>20,954</td>
<td>621</td>
<td>102</td>
<td>853</td>
<td>2,175</td>
</tr>
<tr>
<td>Dyslipidemia</td>
<td>45,208</td>
<td>1,727</td>
<td>186</td>
<td>1,440</td>
<td>4,038</td>
</tr>
<tr>
<td>Hypertension</td>
<td>60,121</td>
<td>2,113</td>
<td>140</td>
<td>1,552</td>
<td>5,006</td>
</tr>
<tr>
<td>Obesity</td>
<td>6,759</td>
<td>227</td>
<td>52</td>
<td>173</td>
<td>485</td>
</tr>
<tr>
<td>Pain</td>
<td>81,501</td>
<td>3,068</td>
<td>575</td>
<td>2,182</td>
<td>6,037</td>
</tr>
<tr>
<td>Baseline lipid panel values‡§</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥1 LDL-C value available</td>
<td>26,653</td>
<td>775</td>
<td>865</td>
<td>1,843</td>
<td>5,319</td>
</tr>
<tr>
<td>LDL-C &lt;100 mg/dL</td>
<td>8,279</td>
<td>137</td>
<td>89</td>
<td>977</td>
<td>2,518</td>
</tr>
<tr>
<td>LDL-C &lt;70 mg/dL</td>
<td>1,803</td>
<td>35</td>
<td>5</td>
<td>418</td>
<td>637</td>
</tr>
<tr>
<td>≥1 HDL-C value available</td>
<td>26,964</td>
<td>792</td>
<td>856</td>
<td>1,859</td>
<td>5,343</td>
</tr>
<tr>
<td>HDL-C &gt;40 mg/dL for males, &gt;50 mg/dL for females</td>
<td>17,655</td>
<td>437</td>
<td>539</td>
<td>1,106</td>
<td>3,380</td>
</tr>
<tr>
<td>≥1 triglyceride value available</td>
<td>27,196</td>
<td>804</td>
<td>860</td>
<td>1,865</td>
<td>5,377</td>
</tr>
<tr>
<td>Triglycerides &lt;150 mg/dL</td>
<td>17,757</td>
<td>459</td>
<td>500</td>
<td>1,158</td>
<td>3,480</td>
</tr>
<tr>
<td>≥1 total cholesterol value available</td>
<td>27,292</td>
<td>808</td>
<td>860</td>
<td>1,870</td>
<td>5,386</td>
</tr>
<tr>
<td>Total cholesterol &lt;200 mg/dL</td>
<td>14,703</td>
<td>307</td>
<td>244</td>
<td>1,359</td>
<td>3,640</td>
</tr>
<tr>
<td>≥1 non-HDL-C value available</td>
<td>26,924</td>
<td>792</td>
<td>854</td>
<td>1,857</td>
<td>5,335</td>
</tr>
<tr>
<td>Non-HDL-C &lt;130 mg/dL</td>
<td>9,780</td>
<td>153</td>
<td>108</td>
<td>1,001</td>
<td>2,701</td>
</tr>
<tr>
<td>Baseline medications</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti-platelet medications</td>
<td>445</td>
<td>9</td>
<td>0.2</td>
<td>13</td>
<td>31</td>
</tr>
<tr>
<td>Antidiabetic medications</td>
<td>12,561</td>
<td>472</td>
<td>7.8</td>
<td>571</td>
<td>1,400</td>
</tr>
</tbody>
</table>

(Continued)
Among all patients, 11.2% had baseline all-cause inpatient hospitalizations, 18.0% ER visits, 89.2% office visits, 84.8% other outpatient visits/services, and 82.6% pharmacy prescriptions. Baseline mean (SD, median) all-cause costs were $8,852 ($25,608, $3,379). Among patients with ≥36 months of follow-up, 10.6% had baseline all-cause inpatient hospitalizations, 17.1% ER visits, 89.9% office visits, 85.9% other outpatient visits/services, and 84.2% pharmacy prescriptions.

Baseline mean (SD, median) all-cause costs were $8,375 ($24,962, $3,490; data not shown in tables or figures).

Follow-up
During the 12-month follow-up period, 49.0% of all patients had all-cause inpatient hospitalizations while 42.0% had ASCVD-related inpatient hospitalizations. Patients on high-intensity statins in all four quarters had the highest proportion of all-cause (87.3%) and ASCVD-related (86.5%) inpatient hospitalizations (Figure 1). In the course of the 12-month follow-up period, mean (SD, median) all-cause...
costs for all patients were $31,443 ($54,040, $15,389) while ASCVD-related costs were $20,289 ($45,159, $4,510). Over the same duration, mean (SD, median) all-cause and ASCVD-related costs for patients on high-intensity statins in all four quarters were $56,324 ($52,954, $43,714) and $50,015 ($49,969, $38,202), respectively. During this period, patients with LDL-C reduction >50% had mean (SD, median) all-cause costs of $42,988 ($53,980, $31,164), followed by patients with LDL-C <70 mg/dL ($40,969 [$53,143, $28,118]) and patients with LDL-C <100 mg/dL ($33,418 [$48,195, $19,463]). Mean (SD, median) ASCVD-related costs over 12 months of follow-up among patients with LDL-C reduction >50%, LDL-C <70 mg/dL, and LDL-C <100 mg/dL were $34,448 ($50,842, $23,700), $31,771 ($48,609, $20,146), and $24,577 ($43,824, $8,632), respectively (Figure 2). The distributions of cumulative HCRU and costs over 36 months of follow-up among all patients and subgroups were similar to those over 12 months of follow-up (Figures S1 and S2).

### Multivariable analysis results

**Baseline factors associated with all-cause and ASCVD-related health care costs at 12-month follow-up**

Regression models were used to evaluate patients’ all-cause (n = 26,388) and ASCVD-related (n = 26,376) costs among subsamples of patients derived by excluding those with no baseline lipid values or with zero all-cause/ASCVD-related costs at follow-up. As shown in Figure 3, older age, health plan location including South and West (vs. Midwest), higher QCI, index ACS, index ACD, baseline depression, pain, obesity, and chronic kidney disease, baseline use of anti-hypertensive agents, anti-diabetic medications, and digoxin, and higher baseline all-cause health care costs (in thousands) were positively associated with all-cause health care costs at 12-month follow-up (p < 0.05). Factors negatively associated with all-cause health care costs at 12-month follow-up (p < 0.05) included female gender, Northeast plan (vs. Midwest), HMO (vs. PPO), Medicare Advantage Plans, index CHD,
index PAD, baseline dyslipidemia, baseline goal attainment of LDL-C (<100 mg/dL), HDL-C (>40/50 mg/dL for males/ females), triglycerides (<150 mg/dL), and total cholesterol level (<200 mg/dL). Similar findings were reported for ASCVD-related health care costs at 12-month follow-up (Figure S3).

**Discussion and conclusion**

The study provided insights into demographics and clinical characteristics, short-term and long-term LLM utilization patterns, and HCRU and costs of newly diagnosed ASCVD patients in a real-world environment. It incorporated features from the older and current guidelines to expand the scope and volume of information on disease burden and gaps in care among ASCVD patients as defined by the 2013 ACC/AHA guidelines.5

In this study population, only a small proportion of patients initiated high-intensity statins within 6 months of an ASCVD diagnosis, a trend that persisted through the 12- and 36-month follow-up assessments. Low rates of high-intensity statin fills have been reported in several studies, for example, Virani et al21 (36.5% among cardiovascular disease patients who received statins within a 1-year observational period) and Rosenson et al22 (35.0% within 365 days of discharge among patients with hospitalizations for a CHD event). Particularly concerning is the finding that at both 12- and 36-month follow-up, approximately half of the patients with ASCVD were receiving no LLM. These results showed that the treatment received by ASCVD patients prior to implementation of the 2013 ACC/AHA guidelines was very different from what the 2013 ACC/AHA guidelines recommend. Pencina et al14 estimated that the 2013 ACC/AHA guidelines would increase statin eligibility by 11% in the USA, or by 12.8 million patients when compared with the ATP-III guidelines. However, the current study results (large proportion of patients not on high-intensity statins or not on any LLM, and large proportion of patients with index LLM discontinuation) indicate that there may be a need for considerable modifications in prescribing patterns designed to help patients access the potential benefits of high-intensity statins5,23–25 and improving treatment outcomes as indicated in the 2013 ACC/AHA guidelines.5

Our findings indicated that ASCVD patients, who were on intensive statin therapy according to the 2013 ACC/AHA guideline recommendations2 or met the NCEP ATP III guidelines13 on LDL-C goal attainment, had significant HCRU and costs associated with residual risk. These findings most likely reflect more aggressive statin use by patients considered to be at highest risk (with risk, rather than statin use as the driver of HCRU). As the 2013 ACC/AHA guidelines become better entrenched and the recommendations for high-intensity statin therapy proliferate across a broader spectrum of ASCVD patients with varying severity and risk profiles, it seems plausible for the economic burden associated with high-intensity statin therapy to decrease, perhaps eventually leading to overall health care savings. As new technologies emerge with the ability to further optimize the lipid profile beyond what high-intensity statin therapies can achieve alone, there may
be similar opportunities to optimize residual risk and impact HCRU and costs among patients with clinical ASCVD.

The study also indicated that age, gender, baseline comorbid conditions, baseline use of specific medications, baseline lipid profiles, and the type of index ASCVD were significantly associated with all-cause and ASCVD-related health care costs. Female gender may be negatively associated with all-cause and ASCVD-related health care costs because there may be a tendency for women to be undertreated,\textsuperscript{26} although relevant questions such as gender-based help-seeking decisions in cardiology are quite complex and not well understood.\textsuperscript{26} Further study is needed to test whether this is changing in the absence of specific gender differences for treating ASCVD based on the more recent ACC/AHA guidelines.\textsuperscript{27} Geographic location and health insurance type are also significantly associated with health care costs among ASCVD patients in this study. Compared to patients with health plans located in the Midwest, those enrolled in Northeast health plans were significantly associated with lower all-cause health care costs, while those with health plans located in the South or West regions were significantly associated with higher all-cause health care costs.
Furthermore, patients enrolled in PPOs were significantly associated with higher all-cause health care costs when compared to patients enrolled in other types of health plans (HMOs or other). These multivariable results suggested that HCRU and costs of ASCVD patients were impacted by multiple patient demographic and clinical characteristics. Clinicians may want to take these factors into consideration to achieve optimal management of ASCVD patients according to the 2013 ACC/AHA guideline recommendations.

Limitations
The study results must be approached with caution because of limitations associated with transactional claims data repurposed for research. First, in addition to the potential for miscoding, incompleteness and other errors, a claim for a filled prescription does not necessarily mean that the medication was consumed or taken as prescribed. On the other hand, the absence of a prescription claim does not necessarily mean that a medication was not taken; for example, patients may purchase medications directly or acquire them from pharmacies that do not submit claims or obtain professional samples from physicians. Thus, LLM utilization in this study could have been underestimated or overestimated. Furthermore, patients with ASCVD have a class 1 (level of evidence –A) recommendation for statin therapy “and” aspirin (except where contraindicated).28 However, in claims-based studies, nonprescription antiplatelet therapy (such as aspirin) use cannot be evaluated, underscoring the challenges of obtaining a full utilization picture. Therefore, the numbers listed in Table 1 (n = 8,785 [6.9%]) refer only to prescription antiplatelet therapy. In addition, as only some subgroups of patients with ASCVD carry a recommendation for prescription antiplatelet therapy (either because of intolerance to aspirin or the need for dual therapy), it is expected that usage of prescription antiplatelet therapy would be lower than that of LLMs. Second, a diagnosis code on a medical claim does not necessarily indicate the presence of a disease, as a diagnosis code may be incorrectly coded or included as a ruled-out diagnosis. To address this issue, we required ≥1 inpatient or ER visit with any ASCVD ICD-9-CM diagnosis codes in the primary diagnosis position or ≥2 physician office or other outpatient visits that were ≥30 days apart with the same group of ASCVD ICD-9-CM diagnosis codes for identification of the ASCVD patients. Third, it is generally acknowledged that some patient characteristics that may be expected to affect risk and costs are not available in claims data (family history, smoking status, diet, exercise, severity of ASCVD, etc). Finally, our multivariable analyses were restricted to patients with available laboratory data. These results may not be generalizable to all patients in the HIRD, or to patients in noncommercial health plans or without any health insurance, or to patients who had any LLM use prior to their ASCVD diagnoses.

Conclusion
The findings suggest that treatment for ASCVD patients was not optimal and significant modifications in prescribing patterns should be made toward the use of high-intensity statins to improve treatment outcomes in accordance with the 2013 ACC/AHA guidelines.5 The findings indicated that ASCVD patients had significant residual HCRU and costs. Furthermore, age, gender, geographic location, health insurance type, baseline comorbid conditions, baseline use of specific medications, baseline lipid profiles, and type of index ASCVD were significantly associated with all-cause and ASCVD-related health care costs. Unmet needs, including association of suboptimal treatment with future cardiovascular events, and cost burdens of ASCVD patients merit additional investigation.

Acknowledgments
Bernard B Tuuli, MSc, provided writing and other editorial support for this manuscript. We wish to recognize Debra Wertz, PharmD, Senior Director at HealthCore, Inc., for her critical review and guidance throughout the study, and in the preparation of this manuscript. This study was supported by Eli Lilly and Company.

Disclosure
Thomas P Power is an employee of AIM Specialty Health, a wholly owned subsidiary of Anthem, Inc. Xuehua Ke, Mark J Cziraky, Michael Grabner, John J Barron, and Ralph Quimbo are employees of HealthCore, Inc., a wholly owned subsidiary of Anthem, Inc., under contract with Eli Lilly and Company for the conduct of this study. Nicole Gidaya Bonine was an employee of HealthCore, Inc., under contract with Eli Lilly and Company for the conduct of this study at the time of the study. Zhenxiang Zhao and Burkhard Vangerow are employees and stock/shareholders of Eli Lilly and Company. Peter P Toth is an employee of CGH Medical Center and an adjunct associate professor at Johns Hopkins University School of Medicine, under contract with HealthCore, Inc.; has relationships for the following: speakers bureau – Amarin Corporation, AstraZeneca Plc, Genzyme Corporation, GlaxoSmithKline Plc, Kowa Pharmaceuticals America, Inc., and Merck & Co., Inc.; consultant – Amgen, AstraZeneca Plc, Atherotech Diagnostics.
The authors report no other conflicts of interest in this work.

References
Supplementary materials

**Figure S1** Cumulative all-cause and ASCVD-related HCRU over 36-month follow-up.

Note: The percentages in the figure show the percentage of patients with ≥1 specific visit or pharmacy fill.

**Abbreviations:** ASCVD, atherosclerotic cardiovascular disease; ER, emergency room; HCRU, health care resource utilization; LDL-C, low-density lipoprotein cholesterol.

**Figure S2** Mean cumulative all-cause and ASCVD-related costs over 36-month follow-up.

Note: Costs were adjusted to 2013 dollar values based on the consumer price index for medical care from the US Bureau of Labor Statistics.19

**Abbreviations:** ASCVD, atherosclerotic cardiovascular disease; LDL-C, low-density lipoprotein cholesterol.
## Table S1 ASCVD groups

<table>
<thead>
<tr>
<th>Group</th>
<th>Type</th>
<th>Diseases/events</th>
<th>ICD-9-CM diagnosis code</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>ACS</td>
<td>MI</td>
<td>410.xx</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Unstable angina</td>
<td>411.1x, 411.81, 411.89</td>
</tr>
<tr>
<td></td>
<td>CHD</td>
<td>Old MI</td>
<td>412.xx</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Stable angina</td>
<td>413.xx</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Coronary atherosclerosis</td>
<td>414.0x, 414.2x, 414.3x, 414.4x, 414.8x</td>
</tr>
<tr>
<td>2</td>
<td>ACD</td>
<td>Ischemic stroke</td>
<td>433.x1, 434.x1</td>
</tr>
<tr>
<td>3</td>
<td>PAD</td>
<td>PAD</td>
<td>440.2x, 440.3x, 440.4x, 443.9x, 445.0x, 447.1x</td>
</tr>
</tbody>
</table>

**Abbreviations:** ACD, atherosclerotic cerebrovascular disease; ACS, acute coronary syndrome; ASCVD, atherosclerotic cardiovascular disease; CHD, coronary heart disease; MI, myocardial infarction; PAD, peripheral artery disease; TIA, transient ischemic attack.

---

![Figure S3 GLM results: baseline factors associated with ASCVD-related health care costs over 12-month follow-up.](https://www.dovepress.com/)

**Notes:** Dependent variable: ASCVD-related health care costs at 12-month follow-up. Baseline medications of interest: anti-claudication medications, antidiabetic medications, antihypertensive medications, digoxin, prescription antiplatelet and anticoagulant medications, and prescription omega 3 fatty acids. Costs were adjusted to 2013 dollar values based on the consumer price index for medical care from the US Bureau of Labor Statistics.

**Abbreviations:** ACD, atherosclerotic cerebrovascular disease; ACS, acute coronary syndrome; ASCVD, atherosclerotic cardiovascular disease; CHD, coronary heart disease; MI, myocardial infarction; PAD, peripheral artery disease; TIA, transient ischemic attack.